Natco Pharma launches first generic alternative to Revlimid in Canadian market

Natco Pharma

Natco Pharma (Canada) Inc., a subsidiary of Natco Pharma, announced today the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid to be approved by Health Canada.

Natco Pharma was quoting at Rs 966.90, up Rs 26.30, or 2.80 percent on the BSE.

News Source:- MoneyControl

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button